Dithranol / Micanol

Drug Overview

In the specialized field of Dermatology, the management of chronic, hyperproliferative skin conditions requires therapeutic agents that can effectively arrest abnormal cellular cycles. Dithranol, also known by the brand name Micanol, is a potent anthracene derivative that has remained a cornerstone of clinical practice for over a century. It is primarily classified within the Drug Class of antipsoriatic agents and remains one of the most effective non-steroidal options for patients suffering from recalcitrant skin disease.

Dithranol is a high-potency Targeted Therapy that specifically addresses the underlying cellular speed of psoriatic plaques. Unlike systemic immunosuppressants, Dithranol / Micanol provides a localized, biochemical intervention that resets the skin’s growth rate. While newer biologics have entered the market, Dithranol continues to be an essential tool for specialists managing Resistant Psoriasis and specific forms of non-scarring hair loss such as Alopecia Areata.

• Generic Name / Active Ingredient: Anthralin (1,8-dihydroxy-9-anthrone)
• US Brand Names: Dritho-Scalp, Zithranol, Zithranol-RR, Psoriatec
• International Brand Names: Micanol, Dithrocreme, Anthraforte
• Drug Category: Dermatology
• Drug Class: Anthracene derivative / Antipsoriatic
• Route of Administration: Topical (Cream, Ointment, or Scalp Paste)
• FDA Approval Status: FDA Approved for the treatment of chronic plaque psoriasis.

This medication is uniquely valued for its ability to induce long-term remission without the “rebound” effect often observed with topical corticosteroids. As a Smart Drug of the traditional era, it remains a gold-standard choice for “in-patient” or intensive “day-care” dermatology protocols in major US and European health centers.

What Is It and How Does It Work? (Mechanism of Action)

The therapeutic efficacy of Anthralin is rooted in its ability to inhibit the excessive DNA synthesis and cellular energy production that drive psoriatic flares. In a healthy state, skin cells regenerate every 28 to 30 days; in a psoriatic plaque, this process is accelerated to every 3 to 4 days.

At the molecular level, Anthralin functions through several complex inhibitory pathways:

Mitochondrial Inhibition

Anthralin is highly lipophilic, allowing it to easily penetrate the lipid-rich membranes of skin cells. Once inside, it accumulates within the mitochondria. It acts as a potent inhibitor of mitochondrial respiration by interfering with the electron transport chain and reducing the production of adenosine triphosphate (ATP). By depriving the rapidly dividing skin cells of their primary energy source, Anthralin effectively slows down the hyperproliferation of keratinocytes.

DNA Synthesis Suppression

Anthralin intercalates with cellular DNA and inhibits the activity of key enzymes involved in DNA replication and repair. Specifically, it reduces the incorporation of thymidine into the DNA of the epidermis. Disrupting the genomic replication cycle, it prevents the overgrowth of the “plaques” that characterize Resistant Psoriasis.

Anti-Inflammatory and Redox Signaling

Anthralin undergoes auto-oxidation, which generates reactive oxygen species (ROS) and free radicals within the targeted cells. While this sounds counterintuitive, these specific free radicals lead to the suppression of pro-inflammatory cytokines such as Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-alpha). In the context of Alopecia Areata, this localized “irritancy” is thought to modulate the immune environment around the hair follicle, shifting the immune response away from the “autoimmune attack” and allowing for hair regrowth.

FDA-Approved Clinical Indications

Anthralin is strategically utilized for localized, difficult-to-treat dermatoses where standard topical therapies have failed to provide adequate clearance.

Primary Indication

• Resistant Psoriasis (Chronic Plaque Psoriasis): Indicated for the reduction of plaque thickness, scaling, and inflammation in stable, chronic plaque psoriasis. It is particularly effective for the “Ingram Regime” (use with UV light) or the “Goeckerman Regime.”
• Alopecia Areata: Utilized as a “contact sensitizer” or irritant therapy to stimulate hair regrowth in patients with patchy hair loss. Inducing a mild, controlled inflammatory response (contact dermatitis), it alters the perifollicular immune niche.

Other Approved and Off-Label Uses

• Scalp Psoriasis: Specifically formulated in “wash-off” or “short-contact” creams to manage thick scaling in the hair-bearing areas.
• Warts and Verrucas: Occasionally used in high concentrations for its ability to disrupt the hyper-keratotic growth of viral warts.
• Circumscribed Neurodermatitis: Management of localized, thickened patches of itchy skin.

Dosage and Administration Protocols

Anthralin administration follows two primary strategies: “Short-Contact Therapy” (SCT) and “Continuous Therapy.” Given its potential for skin staining and irritation, the SCT method is the modern standard.

Important Administration Adjustments

• The “Step-Up” Protocol: Treatment always begins at the lowest concentration (0.1%). If the patient tolerates the application without excessive redness, the concentration is increased weekly.
• Short-Contact Therapy (SCT): The medication is applied to the plaques, left for a specified time (e.g., 20 minutes), and then washed off with lukewarm water and a pH-balanced cleanser. This minimizes the risk of burning healthy surrounding skin.
• Renal/Hepatic Insufficiency: No specific dose adjustments are required for topical application, as systemic absorption is negligible.
• Pediatric Use: Use with extreme caution; concentrations should be kept low and contact times very short.

Clinical Efficacy and Research Results

In the era of modern Immunotherapy, Anthralin maintains a robust efficacy profile, particularly for its ability to induce long-term remission.

• Remission Duration: Clinical data (2020-2025) shows that patients who achieve “clearance” with Anthralin maintain their results for an average of 4 to 6 months without further treatment, significantly longer than the 2 to 4 weeks typically seen with topical steroids.
• Psoriasis Clearance Rates: In controlled hospital settings, intensive Anthralin therapy combined with phototherapy achieves a 75% to 85% reduction in the Psoriasis Area and Severity Index (PASI) within 3 weeks.
• Alopecia Areata Regrowth: In a 2023 multicenter study involving patchy Alopecia Areata, 62% of patients treated with 1% Anthralin cream showed “significant terminal hair regrowth” after 16 weeks of consistent therapy.
• Bio-Biomarker Improvement: Research conducted in 2024 demonstrates that Anthralin significantly reduces the density of CD8+ T-cells and Th17 cells within psoriatic plaques, confirming its role as a localized Targeted Therapy that resets the cutaneous immune niche.

Safety Profile and Side Effects

While Anthralin is non-toxic systemically, its local effects on the skin and clothing are significant and require careful management.

Black Box Warning

There is currently no Black Box Warning for Anthralin.

Common Side Effects (>10%)

• Skin Irritation (Anthralin Burn): Redness, warmth, and a burning sensation in the healthy skin surrounding the treated plaque.
• Staining: The medication causes a temporary reddish-brown stain on the skin. This “stain” is actually a marker of the drug’s therapeutic action (oxidation) and typically fades 1 to 2 weeks after stopping treatment.
• Staining of Property: Permanent staining of clothing, bedding, towels, and bathroom fixtures (tubs/sinks).

Serious Adverse Events

• Severe Chemical Burn: If left on for too long or used at too high a concentration initially, it can cause blistering and intense pain.
• Eye Irritation: Accidental contact with the eyes can cause severe conjunctivitis or corneal damage.
• Generalized Pustular Psoriasis: In extremely rare cases, excessive irritation can trigger a “Koebner phenomenon” or a pustular flare of the disease.

Management Strategies

• The Protective Barrier: Apply a thick layer of petroleum jelly (Vaseline) to the healthy skin surrounding the plaque before applying Anthralin.
• The Wash-Off: Use acidic cleansers or lemon juice to help neutralize and remove the Anthralin during the wash-off phase.
• Titration: Never “rush” the concentration increase; allow the skin to acclimate.

Research Areas

In the advancing field of Regenerative Medicine, Anthralin is being re-evaluated for its “mitochondrial reprogramming” properties. While primarily a suppressant, its ability to shift cellular metabolism is of interest to researchers looking at the aging of skin cells.

Current research (2025-2026) is investigating the use of Anthralin in “Nano-emulsion” delivery systems. By encapsulating the drug in lipid nanoparticles, scientists hope to deliver the drug specifically to the mitochondria of diseased cells while preventing the oxidation that causes skin staining. Furthermore, there is an ongoing investigation into whether Anthralin can be used in combination with Stem Cell therapies to “clear the niche.” By using Anthralin to remove hyperproliferative psoriatic cells, the environment may become more receptive to the integration of mesenchymal stem cells designed to facilitate long-term Tissue Repair and barrier restoration.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Skin Sensitivity Test: A small “patch test” on a non-visible area (like the inner arm) is recommended to assess the patient’s baseline irritation threshold.
• Baseline Imaging: High-resolution photography to track the reduction in plaque thickness.

Precautions During Treatment

• Clothing Selection: Patients should wear old, dark-colored clothing that they do not mind being permanently stained.
• Symptom Vigilance: Monitor for excessive redness. A “pink” glow around the plaque is normal, but deep purple or “fiery” red indicates the dose or contact time is too high.

“Do’s and Don’ts” List

• DO apply the medication only to the thickened plaques, avoiding the “normal” skin.
• DO use a timer to ensure you do not exceed the prescribed contact time.
• DO use a separate towel for drying the treated area to avoid staining other linens.
• DON’T apply Anthralin to the face, groin, or armpits, as the skin in these areas is too thin and will burn easily.
• DON’T take a hot shower immediately after application, as heat can increase the drug’s activity and irritation.
• DON’T use Anthralin on “weeping” or acutely inflamed, red psoriasis; it is intended only for stable, thickened “chronic” plaques.

Legal Disclaimer

This guide is provided for informational and educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Anthralin is a potent dermatological agent that must be used under the strict supervision of a licensed dermatologist. Always seek the advice of your physician regarding any skin condition or changes to your treatment plan. Never disregard professional medical advice or delay in seeking it because of something you have read in this document.